Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM Neisseria lactamica Expressing NadA Challenge
NCT03630250Phase 1Completed
- Sponsor
- University of Southampton
- Start
- Oct 2018
- Primary completion
- Sep 2019
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, open-label trial of neisseria lactamica expressing neisserial adhesin A in meningococcal disease (3 arms), sponsored by University of Southampton. Primary endpoints: Respiratory Rate at Day 4, Body Temperature at Day 4 and 2 more. Started Oct 2018; status: completed.
02
Drugs
neisseria lactamica expressing neisserial adhesin A
03
Conditions
meningococcal disease
Beyond the preview
Go deeper on NCT03630250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03630250.